Investor presentation from Financial Stockholm is now available
Lumito AB’s (publ) ("Lumito" or the "Company") CEO Sanna Wallenborg presented the Company, the ongoing rights issue, and future plans at Financial Stockholm's event in Stockholm yesterday. The presentation is now available on Lumito’s website. On the website, the Company has also published other material connected to the ongoing rights issue. Click here to take […]
Lumito presents at Financial Stockholm on the 21st of October
Lumito AB (publ) ("Lumito" or the "Company") is currently conducting a rights issue, with a subscription period ending on the 30th of October 2025. Lumito's CEO, Sanna Wallenborg, will present the Company, the rights issue, and future plans at Financial Stockholm's event at Hotel Scandic Anglais in Stockholm on the 21st of October 2025. Financial […]
Concept Life Sciences adds Lumito’s tissue analysis solution to its customer offering following positive results from the SCIZYS platform evaluation
Lumito AB (publ) ("Lumito" or the "Company") announces that Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences and pharma industry, has added Lumito's advanced tissue analysis technology to its customer offering,following a joint development collaboration leading to positive results from its evaluation of the SCIZYS platform. "This is an […]
Lumito AB publishes prospectus in connection with rights issue of units of approximately SEK 60 million
THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD BE CONTRARY TO OR REQUIRE […]
Lumito AB announces terms of rights issue of units of approximately SEK 60 million
THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD BE CONTRARY TO OR REQUIRE […]
Lumito AB publishes white paper on the use of SCIZYS for high-sensitivity analysis of the breast cancer biomarker HER2 in tissue
Lumito AB (publ) (“Lumito” or the “Company”) has published a white paper highlighting how the Company’s product, SCIZYS, can be used to identify and quantify biomarkers, with a particular focus on the breast cancer biomarker HER2 at very low levels. The ability to measure extremely low HER2 levels has become increasingly important in recent years, […]
Lumito AB at Biomarkers & Precision Medicine UK, NLSDays and Pharma Outsourcing
Lumito AB (publ) (“Lumito” or the “Company”) has participated during the past week in Biomarkers & Precision Medicine UK, held in the United Kingdom, an event focusing on the latest trends and tools within biomarker research. The event brought together leading experts from global pharmaceutical companies, CROs, biotech firms and start-ups, as well as prominent […]
Lumito Selected for Business Sweden’s CATALYST 2025 – Focusing on Expansion in the United Kingdom
Lumito AB (publ) (“Lumito” or the “Company”), which has developed a solution for advanced tissue analysis based on upconverting nanoparticles (UCNPs), has been selected for Business Sweden’s prestigious scale-up programme, Catalyst 2025. The programme brings together Sweden’s most innovative and promising growth companies, with the aim of supporting commercial expansion in a market chosen by […]
Lumito partners in national research collaboration – strengthening the company’s position in advanced tissue analysis
Lumito has become a new partner in “Biobarriers – Health, Disorders and Healing”, a government-funded project focusing on the development of new technologies to improve health, as well as diagnostics and treatments. This research and collaboration initiative focuses on the body’s biological barriers, such as skin and mucous membranes in, for example, the gastrointestinal tract. […]
Lumito and Truly Labs Take the Next Step Together Following Successful Pilot Study – Preparing for Customer Sample Analysis
Lumito AB today announces that its collaboration with Truly Labs has resulted in the completion of a pilot study showing positive results. The next step will be validation with customer samples. The outcomes of this validation will form the basis for Truly Labs’ offering of tissue analysis using Lumito’s product Scizys to its customers. The […]